N EDGE GROUP INC: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from N EDGE GROUP INC?

Yes. FDA’s import refusal records list 3 refused shipment lines declared as made by N EDGE GROUP INC (Canada) whose FDA product code names retatrutide, on Aug 25, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
Canada
City in FDA records
Cambridge
FEI numbers on the lines
3046831305
Refused lines
3
Lines with an Import Alert 66-80 API or powder code
0
Drugs named in the product codes
Retatrutide
Refusal dates
Aug 25, 2026

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether N EDGE GROUP INC is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Aug 25, 2026Canada61PCY78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).1FX-1683942-6/10002/1
Aug 25, 2026Canada61PCY78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).1FX-1683962-4/10002/1
Aug 25, 2026Canada61PCY78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).1FX-1684201-6/10002/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).3

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

3 lines from FDA files read Nov 15, 2026.